F547C7BB-DBF1-4805-A0EA-D8BC36606032
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 85.4796320630749
- age_years
- 31
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.665
- INTERFERON_GAMMA_RESPONSE+0.603
- IL6_JAK_STAT3_SIGNALING+0.602
- INTERFERON_ALPHA_RESPONSE+0.599
- E2F_TARGETS+0.572
- TGF_BETA_SIGNALING+0.559
- ANGIOGENESIS+0.558
- INFLAMMATORY_RESPONSE+0.557
- G2M_CHECKPOINT+0.546
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.532
Top 10 suppressed
- KRAS_SIGNALING_DN-0.335
- OXIDATIVE_PHOSPHORYLATION-0.305
- PANCREAS_BETA_CELLS-0.275
- SPERMATOGENESIS-0.185
- PROTEIN_SECRETION-0.158
- FATTY_ACID_METABOLISM-0.113
- PEROXISOME-0.104
- BILE_ACID_METABOLISM-0.091
- HEDGEHOG_SIGNALING-0.086
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.050
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR934962 | — | — | 0.933 |
| 2 | SRR934864 | — | — | 0.922 |
| 3 | AF0A7BAA-D031-4C9F-91B7-7034F2C49D72 | — | — | 0.919 |
| 4 | SRR934845 | — | — | 0.918 |
| 5 | 25B5E54F-5858-454C-9B23-440A82450912 | — | — | 0.918 |
| 6 | SRR934881 | — | — | 0.918 |
| 7 | SRR934934 | — | — | 0.918 |
| 8 | SRR934782 | — | — | 0.917 |
| 9 | SRR934747 | — | — | 0.914 |
| 10 | SRR934753 | — | — | 0.912 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 40 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.665 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.603 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.602 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.599 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.572 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.559 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.558 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.557 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.546 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.532 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.515 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.483 | Idelalisib | — uncovered |
| APOPTOSIS | 0.477 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.414 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.398 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.379 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.379 | Inavolisib | — uncovered |
| COMPLEMENT | 0.377 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.364 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.344 | Inavolisib | — uncovered |